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Heparin  cofactor I1 (HC) is a plasma  serine  protein- 
ase inhibitor (serpin) that inhibits a-thrombin in a 
reaction  that is dramatically  enhanced  by  heparin  and 
other glycosaminoglycans/polyanions. We investigated 
the glycosaminoglycan binding  site  in HC by: (i) chem- 
ical modification with  pyridoxal 5"phosphate (PLP) 
in  the absence and presence of heparin  and  dermatan 
sulfate;  (ii) molecular  modeling; and (iii)  site-directed 
oligonucleotide  mutagenesis. Four  lysyl  residues (173, 
252, 343, and 348) were  protected  from modification 
by heparin  and  to a lesser  extent by dermatan  sulfate. 
Heparin-protected  PLPHC  retained  both  heparin co- 
factor and dermatan sulfate cofactor activity while 
dermatan  sulfate-protected  PLPHC  retained some der- 
matan  sulfate  cofactor  activity  and  little  heparin co- 
factor activity. Molecular modeling studies revealed 
that L Y S ' ~ ~  and L Y S ~ ' ~  are within a region  previously 
shown  to  contain  residues involved in glycosaminogly- 
can binding. Lys343 and Lys348 are distant  from  this 
region,  but  protection by heparin  and  dermatan  sulfate 
might  result  from a conformational  change  following 
glycosaminoglycan binding to the inhibitor. Site-di- 
rected  mutagenesis of L Y S ' ~ ~  and Lys343 was  performed 
to  further dissect the  role of these  two  regions  during 
HC-heparin  and  HC-dermatan  sulfate  interactions. 
The Lys343 + Asn or Thr  mutants  had  normal or only 
slightly  reduced  heparin or dermatan  sulfate  cofactor 
activity and eluted from heparin-Sepharose at the 
same ionic strength as native  recombinant HC. How- 
ever, the L Y S ' ~ ~  + Gln or Leu mutants had greatly 
reduced  heparin  cofactor  activity and  eluted  from hep- 
arin-Sepharose at a significantly  lower  ionic  strength 
than  native  recombinant HC but  retained  normal  der- 
matan sulfate cofactor activity. Our results demon- 
strate  that L Y S ' ~ ~  is involved in  the  interaction of  HC 
with  heparin  but not with  dermatan  sulfate,  whereas 
Lys343  is  not critical  for HC binding  to  either glycosa- 
minoglycan.  These data provide further evidence  for 
the  determinants  required  for glycosaminoglycan 
binding  to HC. 
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Heparin cofactor I1 (HC)l  and  antithrombin I11 (AT)  are 
members of the family of serine  proteinase  inhibitors  (serpins) 
in  human  plasma.  Both  proteins  inhibit  proteinases by form- 
ing a covalent complex with  the  proteinase  active  site  in a 1:l 
molar  ratio (1-3). Although AT  inhibits  most of the  protein- 
ases involved in coagulation, HC exerts its anticoagulant 
effect by specifically inhibiting  thrombin (2, 4). 
Heparin  is a highly negatively charged glycosaminoglycan 
composed of alternating residues of glucosamine and  uronic 
acid (5). Heparin  increases by several orders of magnitude  the 
i n  vitro and ex vivo rates of thrombin  inhibition by both  AT 
and  HC (1, 6, 7). Dermatan  sulfate is another glycosamino- 
glycan, consisting of alternating galactosamine and uronic 
acid residues, which acts specifically on HC inhibition of 
thrombin  and does not  accelerate  the  inhibition of any coag- 
ulation  proteinase by AT (4). There  is extensive evidence that 
the effect of heparin  and  dermatan  sulfate is mediated  through 
the  formation of a ternary complex  with both  the  inhibitor 
and  thrombin  binding  to  the  same glycosaminoglycan mole- 
cule (8-11). 
Investigations of natural mutations as well as chemical 
modification studies have  identified two regions  in AT, from 
Gly35 to Glusn and LYS"'~ to Lys'", that are important for 
heparin binding.  Included in  these regions are several essen- 
tial lysyl and  arginyl residues  which are  thought  to  interact 
with  the negatively charged glycosaminoglycans (12-32). Mo- 
lecular  modeling studies,  using  the crystallographic data from 
the related serpin a,-proteinase inhibitor (al-PI; 29), have 
shown that these two regions of AT are also close in the 
tertiary  structure of the molecule and may together form the 
heparin  binding  site  in  AT  (26). 
HC shows little homology to  the G1y3' to Glu5" region of 
AT, but extensive homology to the Lyslo7 to L y P  region, 
which extends from L Y S ' ~ ~   t o  Phelgs in HC. This region has 
been suggested as  the  putative glycosaminoglycan binding  site 
in HC (33-35). Lysyl and arginyl residues have also been 
shown to be essential for glycosaminoglycan binding by HC 
(30, 34, 36) and specific residues in this region have been 
shown to  be  important for these  interactions (34, 35, 37). In 
this study we used pyridoxal 5'-phosphate (PLP) to selec- 
tively modify lysines  in the absence and presence of heparin 
and dermatan sulfate in order to discover lysines in HC 
possibly involved in  binding  to  these glycosaminoglycans. We 
evaluated these results and studied the structure of HC by 
computer-assisted molecular modeling. We then used site- 
' The abbreviations used  are:  HC, heparin cofactor 11; serpin, serine 
proteinase inhibitor; AT, antithrombin 111; (uI-PI, al-proteinase in- 
hibitor; PLP, pyridoxal 5"phosphate; PLPHC, heparin cofactor I1 
modified by pyridoxal  5"phosphate;  rHC, recombinant HC; HPLC, 
high-performance liquid chromatography; TPCK-trypsin, tosylphen- 
ylalanylchloromethyl ketone-treated  trypsin; Chromozym TH, P - p -  
tosyl-Gly-Pro-Arg-p-nitroanilide. 
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FIG. 1. Tryptic peptide maps of PLPHC. Approximately 1 mg 
of HC modified with PLP in  the absence (panel A )  and in the presence 
of heparin (panel B )  or dermatan sulfate (panel C) were chromato- 
graphed by reverse-phase high-performance liquid chromatography 
as described under “Experimental Procedures.” Phosphopyridoxy- 
lated lysine-containing peptides were detected by absorbance at 325 
nm. Panel D shows detection of all peptides in unprotected HC by 
absorbance at 210 nM. Time scale for all panels is in minutes. 
Absorbance  full scale is 0.1 for panels A-C and 1.5 for panel D. 
directed mutagenesis to further assess the involvement of 
L Y S ’ ~ ~  and Lys343 in glycosaminoglycan binding. 
EXPERIMENTAL PROCEDURES~ 
RESULTS 
Identification of Lysyl Residues in  HC Protected by Heparin 
and Dermatan Sulfate from Phosphopyridoxylatwn-In agree- 
ment with our previous observations (30), when HC was 
modified  in the absence of glycosaminoglycan, an average of 
2.7 mol of PLP were incorporated per mol of HC. In the 
presence of 1 mg/ml heparin or dermatan sulfate an average 
of 1.9 or 2.5 mol  of PLP/mol of HC were incorporated, 
respectively. Increasing the dermatan sulfate concentration 
tenfold did not increase the protection (data not shown). 
Tryptic maps were next produced in order to identify which 
lysines had been  modified. The tryptic peptide map of unpro- 
tected PLPHC showed eight major peaks at  325 nm where 
PLP absorbs (Fig. 1, panel A ) .  These  eight peaks yielded six 
peptides, the sequences of which are shown in Table I. When 
rechromatographed, peaks 2-4 in Fig. 1, panel A ,  gave a 
mixture of the peptides containing and Lys303.  All the 
Portions of this paper (including “Experimental Procedures” and 
Tables 1-111) are presented in miniprint at the end of this paper. 
Miniprint is easily read with the aid of a standard magnifying glass. 
Full size photocopies are included in the microfilm edition of the 
Journal that  is available from Waverly Press. 
other peaks gave one 325-nm peak when rechromatographed. 
The tryptic maps of heparin-protected PLPHC  and der- 
matan sulfate-protected PLPHC (Fig. 1, panels B and C, 
respectively) show that peaks 1, 5, 7, and 8 were reduced in 
the heparin-protected sample and  to a lesser extent in the 
dermatan  sulfate-protected sample. These results also show 
that L y P  and Lys303 were modified to essentially the same 
extent in all three PLPHC samples. The  extent of protection 
was determined  (Table 11). In  heparin-protected  PLPHC both 
LYS’?~  and LysZ5’ showed  only about 20% of the modification 
that they showed in the unprotected sample, whereas Lys3a3 
and Lys348  showed  31 and 57% modification, respectively. The 
protection was not  as extensive in dermatan sulfate-protected 
PLPHC. L Y S ’ ~ ~  and LysZ5’  showed 81 and 57% modification, 
respectively, compared with the unprotected sample, whereas 
Lys343 and Lys348 showed 52 and 74% modification, respec- 
tively, compared with unprotected  PLPHC. 
Interaction of Modified HC with Heparin and Dermatan 
Sulfate-The ability of heparin and  dermatan sulfate to ac- 
celerate thrombin inhibition by the modified HC species  was 
studied. Control experiments showed that all samples had 
normal antithrombin activity (inhibition of thrombin by HC 
in the absence of glycosaminoglycans) consistent with pre- 
vious results (Ref. 30; data  not  shown). Fig. 2 shows thrombin 
inhibition by the various modified HC species as  a function 
of heparin and  dermatan  sulfate  concentration. 
Over a range of 0.1-120 pg/ml heparin the reduced control 
HC sample (treated with sodium borohydride but not PLP) 
showed a normal pattern of increasing and  then decreasing 
inhibition, with a maximum inhibition at 10 pg/ml heparin 
(Fig. 2 A ) .  The modified inhibitors also showed this  pattern, 
although none retained the full activity of the reduced control 
HC. Also, the maximum inhibition was shifted to 40 pg/ml 
heparin, probably due to the repulsion of the heparin by the 
negatively charged PLP moiety. The unprotected PLPHC 
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FIG. 2. Effect of glycosaminoglycan concentration on inhi- 
bition of thrombin by PLPHC. 5 nM thrombin was incubated with 
5 0 - n ~  reduced control HC (W), unprotected PLPHC (O), heparin- 
protected PLPHC (A), or dermatan sulfate-protected PLPHC (A) as 
described under “Experimental Procedures.” Panel A ,  effect of in- 
creasing heparin concentrations (0.1-120 pglml). Panel B,  effect of 
increasing dermatan sulfate concentrations (1-1000 pg/ml). Results 
are expressed as percent of thrombin activity in the absence of 
inhibitor. 
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with similar chemical modification studies with AT (21). 
Heparin-protected PLPHC and dermatan sulfate-protected 
PLPHC retained -66 and -23% heparin cofactor activity, 
respectively. Over a  dermatan  sulfate range of  1-1000 pg/ml, 
the reduced control HC sample again showed a normal pattern 
of increasing and  then decreasing inhibition, with a maximum 
inhibition at 250 pg/ml dermatan  sulfate (Fig. 2 B ) .  Unpro- 
tected PLPHC retained -20% dermatan  sulfate cofactor ac- 
tivity  and  ermatan sulfate-protected PLPHC retained 
-33%, relative to  the reduced control  HC sample. However, 
heparin-protected PLPHC retained 91% dermatan sulfate 
cofactor activity, although twice as much dermatan sulfate 
was necessary to reach maximum inhibition. Thus heparin 
(with a greater extent of lysine protection) was able to protect 
both heparin and  dermatan sulfate cofactor activity in HC, 
whereas dermatan sulfate (with a lesser extent of protection) 
could only minimally protect  dermatan sulfate cofactor activ- 
ity. 
Molecular  Modeling of HC-We utilized computer-assisted 
molecular modeling in order to visualize and  further compare 
the putative glycosaminoglycan binding regions of AT and 
HC. As has been done with AT (26), we modeled HC based 
on  its serpin homologue al-PI. Shown in Fig. 3 are the 4 lysyl 
residues protected in the presence of heparin  and  dermatan 
sulfate from modification by PLP. Also shown are several 
residues in the  LyP5  to  the Phe'"  region of HC known to be 
involved in glycosaminoglycan binding. This region includes 
L Y S ' ~ ~  and is  homologous with the proposed heparin binding 
region  in AT. Lys2'* is nearby with respect to  tertiary  struc- 
ture.  These residues form a region of positive charge on the 
surface of the molecule, which could interact with glycosa- 
minoglycans and  other polyanions. Lys"' and Lys348 are  not 
near the putative binding site,  but  are  in  a region  homologous 
to a region in AT in which lysines were protected by heparin, 
but not found to be essential for heparin binding (23).  These 
residues may  be protected by a conformational change upon 
glycosaminoglycan binding or by nonspecific interactions of 
these residues with the glycosaminoglycans. 
Expression of Recombinant HC-Mutated recombinant HC 
(rHC) molecules were created by two distinct mutagenesis 
techniques resulting in a Leu or Gln substitution for L Y S ' ~ ~  
and  Thr or Asn substitution for Lys343. Each of the mutations 
,"-? 
K343 
FIG. 3. Molecular modeling of HC based on its serpin hom- 
ologue al-PI. The protein backbone is shown in gray. Shown in 
black are  the four lysyl residues protected by heparin  and  dermatan 
sulfate from modification by PLP  and residues  known to be involved 
in glycosaminoglycan binding to HC. 
eliminated the positive charge on the side chain of the amino 
acid. The final construct was expressed in Escherichia coli as 
product of the vector pMON-HCII. Besides the absence of 
the signal peptide, the protein product lacked the  NHp-ter- 
minal 18 amino acid residues and  the post-translational mod- 
ifications of plasma HC and has been characterized previously 
(34, 35). The rHC  variants appeared to be identical in size to 
native rHC and had an apparent molecular  weight  of 55,000 
determined by immunoblot analysis of concentrated lysate 
subjected to sodium dodecyl sulfate-polyacrylamide gel elec- 
trophoresis (not shown). 
Binding of rHC to Heparin Sephurose-Native rHC and 
each of the variants were subjected to heparin-Sepharose 
chromatography to determine their relative affinities for hep- 
arin. Native rHC and both of the Lys343 substitutions were 
eluted from the column with a peak at -0.35 M NaCl suggest- 
ing that  the positive charge of this residue is not necessary 
for the  interaction with heparin (Fig. 4A). With native rHC, 
-10% of the immunoreactive protein was detected in the 
column flow-through, but -25-30% was identified in the flow 
through of the Lys343 --., Thr or Asn variants  (data  not shown). 
Under the same conditions, we have previously demonstrated 
that  the column capacity had not been  exceeded and  that  the 
flow through may represent  denatured rHC (35) .  In  contrast, 
L Y S ' ~ ~  + Leu or Gln resulted in protein products that were 
eluted from heparin-Sepharose at a lower  ionic strength (Fig. 
4B).  The peak of native rHC eluted at -0.38 M NaCl, whereas 
rHC ( L Y s ' ~ ~  + Gln)  and rHC ( L Y s ' ~ ~  + Leu) eluted at -0.26 
and 0.15 M NaC1, respectively. For both of these rHC  variants, 
a small fraction of immunoreactive protein (110%) was de- 
tected in the column flow-through. 
Glycosaminoglycan-independent Thrombin Inhibition by 
rHC Variants-Thrombin inhibition was measured in the 
absence of glycosaminoglycan for native rHC and each of the 
rHC  variants  (Table 111), as described previously (47). Native 
rHC had a second-order rate  constant of 1.1-1.6 X 10' M" 
min" which is -4-fold lower than previously reported by 
Tollefsen et al. (7). Using the same truncated form of native 
rHC, Blinder and Tollefsen (35)  have  previously reported a 
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FIG. 4. Heparin-Sepharose chromatography of rHC and 
rHC variants. One ml of E. coli lysates containing rHC or rHC 
variants was applied to a  2-ml heparin-Sepharose column and eluted 
with a linear gradient of NaC1. An aliquot of each fraction was 
subjected to sodium dodecyl sulfate-polyacrylamide gel electrophore- 
sis  and  the  rHC was detected  on  an immunoblot probed with Iz5I- 
labeled anti-HC IgG. The  amount of HC  in  each fraction was deter- 
mined by densitometry of the immunoblot. The relative amounts 
were normalized against a  peak fraction (=loo) as shown. Panel A: 
0, native rHC; 0, rHC + Thr); ., rHC (Lys"' -+ Am). Panel 
B: 0, native  rHC; 0, rHC ( L Y s ' ~ ~  + Leu); ., rHC L Y S ' ~ ~  -+ Gln). 
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FIG. 5. Effect of glycosaminoglycan concentration on inhi- 
bition of thrombin by rHC variants of LYS"~ and 
Incubations were performed with either 155-168 nM rHC for the 
experiments with variants of Lys343 or 40-48 nM rHC for those of 
variants of L Y S ' ~ ~ .  Thrombin (14 nM) and heparin or dermatan  sulfate 
were added at  the final concentration indicated. Left-hand panels: 0, 
native rHC; 0, rHC ( L Y s ' ~ ~  Leu); H, rHC ( L Y s ' ~ ~  + Gln). Right- 
hand panels: 0, native rHC; 0, rHC (Lys343 + Thr); B, rHC ( L y P  
+ Am). 
value of  5.7 X lo4 M-' min-'. Variations may result from the 
determinations of rHC concentration in the lysate and in the 
amounts of denatured  protein that occur in each preparation. 
The mutation Lys343 + Thr produced only modest changes in 
the second-order rate  constant providing evidence that  the 
reactive site of this  mutant was intact. In contrast, the Lys343 
+ Asn substitution appeared to decrease the second-order 
rate  constant -7-fold, suggesting that  this molecule had an 
altered ability to inhibit proteinases in the absence of glyco- 
saminoglycans. The L Y S ' ~ ~  + Leu and L Y S ' ~ ~  + Gln substi- 
tutions resulted in proteins with very similar rate  constants 
compared with native rHC  and therefore retained their ability 
to inhibit  thrombin. 
Heparin- and Dermatan Sulfate-dependent Thrombin In- 
hibition by rHC Variants-The effects of heparin and der- 
matan sulfate on the thrombin  inhibition by rHC and  rHC 
variants are shown in Fig. 5. In these experiments, native 
rHC inhibited 50% of the thrombin with -3-7 pg/ml of 
heparin  and -4-10 pg/ml of dermatan sulfate. The Lys343 + 
Thr variant required similar heparin  concentrations  and only 
2-%fold more dermatan sulfate than  the native rHC to inhibit 
50% of the thrombin, suggesting that  the charge at Lys343 is 
probably not critical for glycosaminoglycan-dependent inhi- 
bition. However, the Lys343 + Asn variant required -10-fold 
higher concentrations of each glycosaminoglycan for 50% 
inhibition, which  may  be accounted for by the decreased rate 
of thrombin inhibition by this variant in the absence of 
glycosaminoglycan (Table 111). 
In contrast, the rHC molecules containing  substitutions of 
LYS'?~ required at least a 30-fold higher concentration of 
heparin for 50% thrombin inhibition. With  dermatan sulfate, 
however, the L Y S ' ~ ~  + Leu variant showed normal thrombin 
inhibition and  the L Y S ' ~ ~  + Gln variant required only a 2- 
fold higher concentration for 50% inhibition.  These observa- 
tions suggest that  the charge a t   L Y S ' ~ ~  is required for heparin- 
but not  dermatan  sulfate-dependent  thrombin  inhibition. 
DISCUSSION 
The glycosaminoglycans heparin and  dermatan sulfate ex- 
ert their anticoagulant effect in human plasma by increasing 
the inhibition rate of proteinases by the serpins HC and A T  
by as much as 1000-fold (1, 6, 7). In  both cases, binding of 
the glycosaminoglycan to  the inhibitor is necessary for activ- 
ity,  and  this binding is thought  to occur by ionic interactions 
between the negatively charged glycosaminoglycan and posi- 
tively charged amino acids of the inhibitor. Chemical modi- 
fication, natural  mutation,  and site-directed mutagenesis of 
these basic amino acid residues result in inhibitors with 
decreased binding to glycosaminoglycans (12-32). The bind- 
ing site of AT is very  specific for a pentasaccharide sequence 
in heparin, and this sequence contains  a unique 3-0-sulfated 
glucosamine at  the  third position. Glycosaminoglycans and 
other polyanions that do not  contain  these  structures have 
almost no ability to accelerate proteinase inhibition by AT 
(48). HC does not require this specific pentasaccharide se- 
quence for acceleration of thrombin inhibition; in fact, the 
HC/thrombin  inhibition reaction can be accelerated by a wide 
range of polyanions (33,  49-51). 
Even though they have different specificities, it is thought 
that  the glycosaminoglycan binding sites in both HC and AT 
occur in similar regions. Several residues have been shown to 
be specifically involved in heparin binding to AT, and  as  a 
result two regions, Gly35 to Glu5' and Lyslo7 to  LYS'~~, have 
been designated as forming the heparin binding domain of 
AT (16-19,  21,  23,  25,  27, 52). HC contains  a region, L y P 5  to 
Phelg5, that shows extensive homology to  the Lyslo7 to L Y S ' ~ ~  
region of AT (Fig. 6). This region is densely populated with 
positively charged amino acids that could interact with var- 
ious polyanions and is the putative glycosaminoglycan binding 
site in HC. Indeed, recent studies have shown the involvement 
of: (i) Lys'= and possibly  Argla4 and Arglg3 in heparin binding 
and (ii) LyslS5, ArgIa9, Argl'', ArgIg3, and possibly Arg" in 
dermatan  sulfate binding to HC (34, 35, 37). 
In  this study we have utilized several approaches to define 
further  the determinants of the glycosaminoglycan binding 
domain in HC. First, we used chemical modification in  the 
absence and presence of heparir. or  dermatan sulfate to iden- 
tify lysyl residues that might be  involved in glycosaminogly- 
can binding. We identified 4 lysyl residues (173,252,343, and 
348) in HC that we were protected from modification in the 
presence of glycosaminoglycan. 
We then used computer-assisted molecular modeling to 
interpret the above results. L Y S ' ~ ~  wasvery well protected 
from chemical modification by heparin and less so by der- 
matan sulfate. L Y S ' ~ ~  is homologous to a residue in AT that 
has been found to be involved in heparin binding to that 
inhibitor (21). Our model  shows it  to be on the surface of the 
molecule and  thus accessible for interaction with glycosami- 
noglycans. Amphipathic a-helices  are  thought to be a possible 
secondary structure  through which proteins bind to glycosa- 
minoglycans (33, 53). LYS'?~ is located just before the  start of 
such an a-helix (D-helix using the nomenclature of al-PI; 
Refs. 26 and 29) containing  other residues in HC important 
in glycosaminoglycan binding. These  results implicate L Y S ' ~ ~  
in glycosaminoglycan binding to HC, especially in heparin 
interactions. 
LysZ5' was well protected from chemical modification by 
heparin and fairly well by dermatan sulfate. LysZ5' is not 
+ +  
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FIG. 6. Comparison of the glycosaminoglycan binding do- 
mains of AT and HC. Alignment of the Lyslo7 to region of 
AT and the Lys1'j5 to Phe195  region of HC. Crosses denote positively 
charged amino acids. Shown in black are residues known to be 
involved in heparin binding (circles), dermatan sulfate binding 
(squares), or both (diamond). 
Critical Lysyl Residue of Heparin Cofactor II 8133 
within the putative glycosaminoglycan binding of site of HC, 
but from our model it is close to  this region in the  tertiary 
structure of the molecule. LYS'~', ArglS9, Arg'", ArgIg3, and 
possibly Arg'% are known to be  involved in glycosaminoglycan 
binding in HC (34, 35, 37) and  can be seen in Fig. 3 to form 
a surface of positive charge, near LysZs2, that could interact 
with the negatively charged glycosaminoglycans. Lys''' may 
be involved in glycosaminoglycan binding, but  it is also pos- 
sible that interactions of other residues in the putative gly- 
cosaminoglycan binding site lead indirectly to protection of 
this lysyl residue from phosphopyridoxylation. 
Lys343 and Lys348 are also not in the putative glycosamino- 
glycan binding site of HC. These residues were moderately 
well protected by both heparin and dermatan sulfate, with 
Lys343 being somewhat more protected by each glycosamino- 
glycan. In our model Lys343 and Lys348 are also shown to be 
on  the surface of the HC molecule but removed from the other 
residues known to be involved in glycosaminoglycan binding. 
These residues are probably not involved in glycosaminogly- 
can binding and may  be protected from chemical modification 
by a conformational change caused by the glycosaminoglycan 
binding to HC or by nonspecific ionic interactions between 
the glycosaminoglycan and HC. 
Finally, we performed site-directed mutagenesis based on 
the information from the chemical modification and modeling 
studies. We chose L Y S ' ~ ~  as  the most probable residue involved 
in glycosaminoglycan binding and we chose to  mutate Lys343 
in order to investigate the possible involvement of the region 
around  this residue in glycosaminoglycan binding. 
The L Y S ' ~ ~  variants  both bound with less affinity to heparin- 
Sepharose than did the native rHC. These  variant  rHC species 
also showed greatly reduced heparin cofactor activity but 
essentially normal dermatan sulfate cofactor activity. This is 
in agreement with the chemical modification data for LYS"'~. 
Heparin was better able to protect L Y S ' ~ ~  from chemical 
modification than dermatan  sulfate was, implying that  this 
residue interacted more with heparin than with dermatan 
sulfate. Additionally, the heparin-protected PLPHC retained 
heparin cofactor activity, whereas the dermatan  sulfate-pro- 
tected  PLPHC  (with 60% less protection of L Y S ' ~ ~ )  retained 
almost no heparin cofactor activity. These  results suggest that 
L Y S ' ~ ~  is involved in the binding of heparin to HC but is not 
critical for the binding of dermatan  sulfate  to HC. We  believe 
the effects of chemical modification and  mutation of L Y S ' ~ ~  
on heparin binding are due to  the loss of the positive charge 
of this residue and therefore the elimination of an electrostatic 
interaction between the side chain of L Y S ' ~ ~  andheparin. 
However, we cannot rule out  the possibility that  the effects 
on binding result from alteration of the  tertiary structure of 
the glycosaminoglycan binding domain in HC. 
Different results were obtained with the Lys343 variants. 
Both of these variants bound to heparin-Sepharose almost 
identically to native rHC. The heparin cofactor and  dermatan 
sulfate cofactor activities of the Lys343 Thr variant were 
very similar to those of the native rHC. The Lys343 + Gln 
variant had less heparin and  dermatan sulfate cofactor activ- 
ity  than rHC, but  this  can be accounted for by the decreased 
antithrombin activity of this  variant.  These  results indicate 
that Lys343 is not critical for the binding of either glycosami- 
noglycan to HC. 
A thorough understanding of the interaction of glycosami- 
noglycans with AT and HC  is necessary because of the wide- 
spread use of heparin as  an anticoagulant. Various residues 
in  the LydGs to Phelg5 region of HC have been shown to effect 
both heparin and  dermatan sulfate binding and  the mutation 
of Arg"' results in deficient dermatan sulfate binding but 
normal heparin binding (34, 35, 37). In  this study we showed 
that mutation of L Y S ' ~ ~  leads to deficient heparin binding but 
normal dermatan sulfate binding. Thus we can state that 
although heparin and dermatan sulfate bind to the same 
region of HC, they have  specific residues on the protein with 
which they  interact.  Further  and precise determination of the 
nature of these  interactions between glycosaminoglycans and 
AT or HC may ultimately lead to  the development of better 
and more specific anticoagulants. 
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THE ROLE OF LYSWE  173 IN HEPARIN BINDING TO HEPARIN COFACTOR II 
bi 
Herbert C. Whinna. Morey A. Blinder, Mark Srewayk,  
Douglas M. Toliefsen. and Frank C. Church 
EXPERIMENTAL PROCEDURES 
__._ MATERIALS 
HC and a-thrombin were purified as  described previously (1 ,  41. 38). Affinlty purifled 
rabbit anti-HC ant ibodis  were prepared and labeled wirh Nal25I as described previously (39) 
from Sigma. Dermatan sulfate was irom Calbiochem or Sigma. and was treated  with  nitrous acid 
Heparin was obtained courtesy of Dr G. van Dedem of Diosynth BV, Ors, The Netherlands or 
for the removal of conlaminating heparin  and  heparan  sulfate (40). Pyridoxal S-phosphate and 
sodium borohydride were purchased from Sigma. Guanidine hydrochloride (Sequanal grade) 
was purchased  from Pierce. Torylphenyialanylchloromethyl ketone-treated  trypsin (TPCK- 
trypsin) and dithiothreitol were obtained from Cooper-Biomedical and Research Orgamcs, 
substrate Na-p- tosy i -Gly -Pro-Arg-~" l t~~~~ i l ide  (Chromozym  TH) was purchased from 
respectively.  Polybrene and iodoacetic acid were from  Aidrich. The chromogenic thrombin 
Boehringer-Mannheim. All other reagents and buffers were of reagent grade or better. 
or New England Biolabs. DNA sequencing was performed using modified T7 polymerare from 
All restriction endonucleases  and DNA modifying enzymes were products  of Amersham 
United Stater Biochemical Corp. The reagents for oligonucleotide-dlrecled mutagenesis were 
purchased from Amemham. Taq DNA polymerase and other reagents used in the polymerase 
chain  reaction were products of Perkin Elmer Cetus.  The  synthetic  oligonucleotides were 
prowded by the Protein Chemistry Facility of Washington University and were used wlthout 
further purification. 
METHODS 
polyethylene glycol (Mr. 8,0001. pH 8.0, was modified for 15 minutes with a 92-fold excess of PLP 
Chemical Modif imm of HC- HC (20 pM1 in 0.05 M  triethanolamine acetate, 0.1 % 
in the absence and presence of 1 mglml heparin or dermatan  sulfate, at 25 OC and in the dark as 
much as possible. The samples were treated with 0.1 M sodium borohydride (dissolved in  ice- 
cold water1 for another 15 minuta at 0 OC. The  reduced samples were then run over a Sephadex 
6-25 mlumn (1 X 40 cm) equilibrated in 0.05 M  triethanolamine acetate, 0.1 % polyethylene glycol 
IM,= 8,nnn). p~ 8.0 containing 0.25 M N ~ C I  in d e r  to remove the majority of unreacted PLI' 
and sodium borohydride. Fractions containing protein (determined by absorbance at 280 nm 
using an extindon coefficient of 0.593 ml mg-l on-1 for HC) were pmled and  dialyzed against 2 
x 2 hers  of n 05 M triethanolamine amate, 0.1 % polyethylene glycol (M,= 8,non), p~ 8.0 with 0.25 
determined by absorbance at 325 nm using an exfmction coefizcient of 9710 Ad-I cm" (30). 
M NaCi in order to remove any remaining reagents Concentration of P1.P bound to IIC was 
prepared errentially as described (23). The PLPHC specin were denatured by dialysis overnight 
Idenlifiralion of Modified R m d u e s  10 HC- Tryptic digests of the modified proteins were 
against 6  M  guanidine HCI, 0.5 M TIUS, 0.002 M EDTA, pH 8.1 The proteins were reduced and 5- 
carboxymethylated by addition of 1 mg of dithiothreitol. incubated at room temperature for 3 
hours.  followed by the  addition  of 200  pL of 120 mglml ~OdOacetic acid in 1 N NaOII (prepared in 
the dark)  and reaaed  for 15 minutes in dim light. The slimpies were then dialyzed against 2 X 2 
liters of 0.1 M  ammonium bicarbonate overnight. After dialysa 50 p1. of 0.5 mg/ml TPCK-trypsin 
in 1 mM HCI was added  and the rampies  digcrled for 4  hours at 37 OC At that time another 50 pL 
of TKK-trypsin was added  and the samples digested for an additmnal27  hours at  37 'X 
Tryptic maps were produced on a Phenomenex, W-Pow C-18 column 14.6 mm inner 
diameter x 250 mm. with 5 pm particles) at 45 OC and P flow rate of 1 mllmin using a Berkman 
Solvent A w a  0.05 M sodium phosphate, pH 6.5; solvent B was acetonitrile. Solvent strength 
Model 332 gradient iiquid chromatograph with P Hewlelt-Parkard 1WOA diode array detector. 
minutes. The elution was monitored  at 210,280. and 325 nm. Peptides absorbing  at 325 nm werc 
was ,"creased linearly from 1 to 28% solvent B in 100 minutes and then to 62% d v e n t  B in 55 
collected  and  rechromatographed on the same column with solvent A being 0.1% ("/VI 
trifluoroacetic acid in water and solvent B being 0.085% tnfluwoaCetic acid in  acetonitrile. The 
gradient was 1% solvent B to 62% solvent B in 61 minutes. Amino  acid  sequences were 
determined on an Applted Bioryrtems 470A gas phase sequencer with an online Walcls HI'LC. 
Phosphopyridoxylated lysine was Identified by the absence of lhe usual lysme peak 123). 
inhibition of thrombin by the various modifled specles was determmed in thc  foliowing 
Functionol Analysts of Modified  HC- The effect of glycosaminoglycan cOnCentralion On the 
manner. Modified HC species were compared lo a "reduced contr01.. HC treated with sodium 
HEPES, 0.15 M NaCI, 0.1% polyethylene glycol lM,= 8.0001, pH 7.4 were incubated at room 
borohydride but not PLP. In a total volume of 0 1 ml. thrombin (5 nM) and  HC ( 5 0  nM) in 0.02 M 
sulfate El000 pglmll. After 15 monds,  0.8 ml of 150 p~  Chmmozym TH in 0.02 M HEPES, 0.15 
temperature with increasing amounts of glycosaminoglycan (heparin 0.1-120 pglml; dermatan 
M NaCI. 0.1% polyethylene glycol (M,= 8,000). pH 7.4 with enough polybrene to complex the 
g~YCOSaminOg~YCan 11 mg/ml for heparin; 10 mg/ml for dermatan sulfate) was added to the 
reaction mixlUle. The remaining active thrombin was allowed to react with Chromozym TH for 
10 minutes  at which time the reaction was stopped by the  addition of 0.1 ml of glacial acetic acid 
The Samples Were centrifuged lo precipitate any glycosaminoglycan/polybrene mmplex and  the 
amount of Chromozym TH hydrolyzed. measured at 404 nm, was taken to be proportional to 
effect of glycosaminoglycan concentration on the  synthetic  substrate activity of thrombin. 
remailung thrombin activity. Controls, with thrombin  and glycosaminoglycan only, showed no 
Computer-Aided Molrcuhr Modelmg - The amino add  sequencer of HC and al-PI were 
obtained from the literature. The three-dimensional S I T U C I U T ~  of al-PI was obtained from the 
Brookhaven Protein Data Bank based on the work of Loebermann et YI (291. The amino aod 
sequence of al-PI was changed to that  of  HC using the SYBYL/MENDYL software package from 
TRIPOS ASSOCIATES, INC.. St. Louis, MO. Regions lacking coordinates, such as the amino- 
terminus, insertions, or deletmns. were ignored in the simulation. The mutated protein was 
minimized using the force-fieldr in SYBYL/MENDYL. The drawings were made using the 
Tripos NITRO program on a Macintosh n. 
Mulogenesis of HC cDNA- Single  nucleotide  mutagenesis of the Lys343  codon was 
performed in the M13mp18 containing the nonmding  strand of HC by the  method  of  Nakamaye 
and  Ecktein as described previously 141). A Bru 36 I- Xho I fragment of the DNA containing the 
mutation was ligated into the expression vector pMON-HCII and  the  final  plasmid c o n s t r ~ ~ l  was 
confirmed by sequencing using the chain termination method of Sanger et n l  142). 
143). In bnef, sequential SilP-directed mutagenesis was performed in Ml3mpl8 containing  the HC 
Random mutations were generated in the Lys173 codon by the procedure of Wells el d 
cDNA to create a Sac I site at nucleotides 595-600 followed by the  formation  of an R5r II site in 
nucleotides 683-689 (numbered according to Blinder 11 a1 Fig 2; 391. The predicted amino acid 
sequence was not altered by the nucleotide substitutions A 660 bp Bsu 36 I- Xho I fragment  of the 
cDNA which contained both new restriction sites was isolated from the replicative form and 
ligated into similarly digested pMON-HCII that had been digested with mung bean nuclease to 
eliminate I Soc I site in the 3' polylinker region of the HC insert (44). Proper ligation was verified 
by digestion with R S I  II and Ssc 1 and the flnal plasmid ~onstruct was confirmed by didwxy 
requendng of both strands. Approximately 5 pg of the pMON-HCII plasmid was digested wlth 
both restriction enzymes and  the vector product was isolated from  the Small Sac I-Rrr II fragment 
by agarose gel electrophoresis and purified from the gel using "glass mi lk  beads (Gene Clean. 
Biolnl). Five oligonucleotides were synthesized lo span the Sac I-Rsr I1 domain. TWO of the 
oligonucleotider, a 44mcr and a 4lmer. formed the coding strand and three complementary 
oligonudwtider (34, 28, and 30 nucleotides in length) comprised the non-coding strand. The 
sequence of the oligonucleotides varied from  the HC cDNA by replacement of all three positions 
in the  codon for ~ ~ $ 1 7 3  with any nucleotide, allowing for generation of  random  changer at those 
positions. In addition,  the  codon for Arg184 was changed from CGT to CGG to create I Bsp El 
restriction site  that was used for screening. Oligonucleotides were pooled at a final mncentralion 
of 10 pM in H z 0  and 2.5 pl of the pool was phosphorylated with T4 polynucleotide kinase. 
Approximately 25 fmol of the  phosphorylated  oligonucleotide were mixed with -12 (mol of  the 
digested DNA in a buffer containing 25 mM Trir-HCI. 10 mM MgCi2, 10 mM DIT, 4 mM ATP, 
74 DNA ligase was added (1 Weinr unit) and the reaction was incubated at 14 OC for 16 hours 
pH 7.5 and  annealed by heating to 68 OC for 5 min and cooled to rmm temperature over 2 hours. 
Escherichia cola ]MI09 were transformed with a portion of the ligation mix, 24 colonies were 
isolated and amplified, and the plasmid was purified (451. A 448 bp DNA fragment spanning the 
oligonucleotide insert was amplified using  the Taq polymerare chain reaction as described by the 
manufacturer  and  the  fragments were digested  with Bsp El to screen for  the  inserted 
oligonucleotides. Seven plasmids containing the ssp Ei site were sequenced between the Rsr II- 
Sac I sites in both orient st ion^ and of those, two clones were detected that contained only 
mutations in the codon far ~ ~ $ 1 7 3 .  
Critical Lysyl Residue of Heparin Cofactor I1 
Erpresrion of Rrcombinant HC ond f l C  v u r ~ n l s -  For each recombinant HC preparsuon, 
transformed Erchrrtchm rol! JMlOl were grown to an optical density of -1 2 at  550 nrn in 500 m l  
of medium, and expression was induced wilh nalidixic acid according 10 Li el nf (46) The cells 
wcre washed, reruspended in phosphate-buffered salme. and lysed by son~calion The producl 
was rubpcled to ammonium  sulfate precipitatron and the concentration of the rHC was 
determmed by a quant~lative immunoblot as dermibed previously (35). There was no a p p a ~ n l  
difference in the recovery oi  the expressed rHC  cornparfd lo Ihe variant rHC preparations. 
Funclimsl Anofyrir of Recombinant HC and HC uorionlr- Binding of r l I C  to hepann was 
determined using a 2-ml heparin-Sepharore column as described previously (35). Thrombin 
inhibition  was determined in the absence of glycosaminoglycans by incubating 900 pi o i  40-168 
nM rHC. 50 pl of 280 nM thrombin and 50 pl of H z 0  at room temperature At specific tunc$ 100 
HI aliquots W P ~ F  added lo 400 p1 of 100 pM Chrornozym TH and the rate of change of absorbance 
a t  405 n m  was monitored contmuously for 100 seconds The rate of change oi  absorbance WBF 
piOporliOnd lo Ihe Concentration of active thrombin remaining in the incubation The eifect of 
glycosaminog!ycanr was determined using thrombin and rHC at the concentrations used above 
and adding various concentrations of heparin or dermatan sulfate to a final volume ai  100 pl 
Absorbance at 405 nm was determined after Ihe addition of Chromozym TH as described above. 
TABLE 1 
Amino Acid Xquencer of PLP Modified Peptides in 









1.6 x 105 
2.2 x 105 
2 3 X 1 d  
1.1 x 10s 
9 2 x 1 0 4  
1 3 x 1 0 5  
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